Chronic Obstructive Pulmonary Disease Clinical Trial
Official title:
Utilizing Canadian Digital Technology to Prevent and Manage Diabetes, Obesity, and Heart Disease in Patients Living With Congestive Obstructive Pulmonary Disease - A Single-arm Pilot Study
People with Chronic Obstructive Pulmonary Disease (COPD) are at greater risk for Metabolic syndrome (MetS). Although the management of MetS will not cure COPD, it can beneficially impact health outcomes and quality of life through lifestyle modifications. The study aims to determine if using the Digital Metabolic Rehab program, which is based on preventive self-care and includes three key pillars of health: nutrition, fitness, and mindfulness, will be feasible to reduce or reverse MetS for individuals living with COPD.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | September 2024 |
Est. primary completion date | September 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adult patients (18+) - COPD stage 1 or 2 - Identified by their family doctor as having at least two out of five MetS factors - Adjusted body mass index (BMI) between 26 to 40 - Able to provide written informed consent in English Exclusion Criteria: - Inability to speak, read or understand English - Having a medical or physical condition that makes moderate-intensity physical difficult or unsafe - Diagnosis of Type 1 diabetes mellitus or type 2 diabetes mellitus with proliferative diabetic retinopathy, nephropathy (serum creatine > 160 µmol/L), clinically significant neuropathy (defined as absent ankle jerks), severe hyperglycemia (fasting blood glucose > 11 mmol/L), or claudication symptoms - Significant medical co-morbidities, including uncontrolled metabolic disorders (e.g., thyroid, renal, liver), COPD stages 3 or 4, heart failure stage D, stroke, and ongoing substance abuse, undergoing active treatment for cancer - Clinically significant renal failure (.i.e., creatinine > 200 µmol/L) - Diagnosis of psychiatric disorders that would limit the adequate ability to comply with the study protocol - Unable or unwilling to use technology to meet with the healthcare team and My Viva Plan to manage self-care |
Country | Name | City | State |
---|---|---|---|
Canada | University of Alberta | Edmonton | Alberta |
Lead Sponsor | Collaborator |
---|---|
University of Alberta | Revive Wellness Inc. |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in quality of life parameters | Changes in scores of quality of life are assessed by the Chronic Respiratory Questionnaire (CRQ). The Items are scaled in Numerical, 7-point modified Likert Scale. Higher scores indicate a better health-related quality of life | From baseline to month 3 and month 6 | |
Other | Changes in SF-12 score | Changes in physical and mental well-being are assessed in 8 domains (physical functioning, role limitations due to physical problems, bodily pain, general health, vitality, social functioning, role limitations due to emotional problems, and mental health) by the Short Form 12 (SF-12). | From baseline to month 3 and month 6 | |
Other | Changes in cardiovascular disease risk | Changes in cardiovascular disease risk by Prospective Cardiovascular Munster scores (PROCAM). PROCAM predicts cardiovascular risk in 10 years (<1% to > 40%). The higher the scores, the greater the cardiovascular risk | From baseline to month 3 and month 6 | |
Other | Well being changes | Changes in well-being are assessed by the World Health Organization Well-Being Index (WHO-5). The raw scores are transformed to a score from 0 to 100, with lower scores indicating worse well-being | From baseline to month 3 and month 6 | |
Other | Mental health | Mental health and depression are assessed by the Patient Health Questionnaire - 9 (PHQ-9). PHQ-9 score will be obtained by adding the score for each question (total points). Scores of 5, 10, 15, and 20 represent cutpoints for mild, moderate, moderately severe and severe depression, respectively | From baseline to month 3 and month 6 | |
Other | Changes in psychosocial determinants of behavioral | Physical Activity Readiness Questionnaire (PAR-Q+) will be used to assess the readiness of participants to engage in physical activity and determines any safety and possible risks that could be impacted by physical activity | From baseline to month 3 and month 6 | |
Other | Changes in hospital admissions rates for exacerbation of COPD | Exacerbation of COPD events is measured by outpatient visits, emergency room visits, and hospitalizations | From baseline to month 6 | |
Other | Changes in hospital admissions rates for myocardial infarction events | Myocardial infarction events are measured by outpatient visits, emergency room visits, and hospitalizations | From baseline to month 3 and month 6 | |
Other | Changes in hospital admissions rates for ischemic stroke events | Ischemic stroke events are measured by outpatient visits, emergency room visits, and hospitalizations | From baseline to month 3 and month 6 | |
Primary | Metabolic Syndrome | Proportion of patients achieving reversal of Metabolic Syndrome (no longer meeting 3 of 5 diagnostic criteria) | Change From baseline to month 3 and month 6 | |
Primary | Waist circumference | Proportion of patients achieving reduction in waist circumference. | Change From baseline to month 3 and month 6 | |
Primary | Blood pressure | Proportion of patients achieving reduction in systolic and diastolic blood pressure. Systolic and diastolic blood pressure will be measured using a standard semi-automatic sphygmomanometer. | Change From baseline to month 3 and month 6 | |
Secondary | Changes in body weight | Changes in body weight will be measured using calibrated digital scale (Health o meter® Professional Remote Display, Sunbeam Products Inc., Fla., USA) | From baseline to month 3 and month 6 | |
Secondary | Changes in and body mass index (BMI) | The intervention's ability to promote changes in BMI (weight and height will be combined to report BMI in kg/m^2) | From baseline to month 3 and month 6 | |
Secondary | Changes in fat mass | Changes in fat mass (kg) by bioelectrical impedance analysis | From baseline to month 3 and month 6 | |
Secondary | Changes in phase angle | Changes in phase angle is assessed by bioelectrical impedance analysis | From baseline to month 3 and month 6 | |
Secondary | Changes in fat-free mass | Changes in fat-free mass (kg) by bioelectrical impedance analysis | From baseline to month 3 and month 6 | |
Secondary | Changes in muscle cross sectional area | Changes in muscle cross sectional area (cm2) by ultrasound | From baseline to month 3 and month 6 | |
Secondary | Changes in muscle echogenicity | Changes in muscle echogenicity by ultrasound | From baseline to month 3 and month 6 | |
Secondary | Changes in muscle strength | Changes in muscle strength assessed by handgrip strength | From baseline to month 3 and month 6 | |
Secondary | Changes in physical performance | Changes in physical performance assessed by 6-minute walk test | From baseline to month 3 and month 6 | |
Secondary | Changes in fitness assessment | Changes in fitness test are assessed using the maximum number of partial curl-ups (up to 25) and push-ups performed in one minute. | From baseline to month 3 and month 6 | |
Secondary | Changes in flexibility test | Changes in trunk flexion range of motion will be evaluated using inertial measuring units during bending in standing position. | From baseline to month 3 and month 6 | |
Secondary | Changes in resting energy expenditure | Changes in resting energy expenditure assessed by indirect calorimetry | From baseline to month 3 and month 6 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05102305 -
A Multi-center,Prospective, OS to Evaluate the Effectiveness of 'NAC' Nebulizer Therapy in COPD (NEWEST)
|
||
Completed |
NCT01867762 -
An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Recruiting |
NCT05562037 -
Stepped Care vs Center-based Cardiopulmonary Rehabilitation for Older Frail Adults Living in Rural MA
|
N/A | |
Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
Completed |
NCT03089515 -
Small Airway Chronic Obstructive Disease Syndrome Following Exposure to WTC Dust
|
N/A | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT05552833 -
Pulmonary Adaptive Responses to HIIT in COPD
|
N/A | |
Recruiting |
NCT05835492 -
A Pragmatic Real-world Multicentre Observational Research Study to Explore the Clinical and Health Economic Impact of myCOPD
|
||
Recruiting |
NCT05631132 -
May Noninvasive Mechanical Ventilation (NIV) and/or Continuous Positive Airway Pressure (CPAP) Increase the Bronchoalveolar Lavage (BAL) Salvage in Patients With Pulmonary Diseases?
|
N/A | |
Completed |
NCT03244137 -
Effects of Pulmonary Rehabilitation on Cognitive Function in Patients With Severe to Very Severe Chronic Obstructive Pulmonary Disease
|
||
Not yet recruiting |
NCT03282526 -
Volume Parameters vs Flow Parameters in Assessment of Reversibility in Chronic Obstructive Pulmonary Disease
|
N/A | |
Completed |
NCT02546700 -
A Study to Evaluate Safety and Efficacy of Lebrikizumab in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 2 | |
Withdrawn |
NCT04446637 -
Acute Bronchodilator Effects of Ipratropium/Levosalbutamol 20/50 mcg Fixed Dose Combination vs Salbutamol 100 mcg Inhaler Plus Ipratropium 20 mcg Inhalation Aerosol Free Combination in Patients With Stable COPD
|
Phase 3 | |
Completed |
NCT04535986 -
A Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of Ensifentrine in Patients With COPD
|
Phase 3 | |
Recruiting |
NCT05865184 -
Evaluation of Home-based Sensor System to Detect Health Decompensation in Elderly Patients With History of CHF or COPD
|
||
Completed |
NCT03256695 -
Evaluate the Relationship Between Use of Albuterol Multidose Dry Powder Inhaler With an eModule (eMDPI) and Exacerbations in Participants With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT03295474 -
Telemonitoring in Pulmonary Rehabilitation: Feasibility and Acceptability of a Remote Pulse Oxymetry System.
|
||
Withdrawn |
NCT04042168 -
Implications of Appropriate Use of Inhalers in Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT03414541 -
Safety And Efficacy Study Of Orally Administered DS102 In Patients With Chronic Obstructive Pulmonary Disease
|
Phase 2 | |
Completed |
NCT02552160 -
DETECT-Register DocumEnTation and Evaluation of a COPD Combination Therapy
|